{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:30:21Z","timestamp":1780083021896,"version":"3.54.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,20]]},"DOI":"10.7759\/cureus.79389","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:19:56Z","timestamp":1740111596000},"source":"Crossref","is-referenced-by-count":1,"title":["Treating a Non-mixed Neuroendocrine Colorectal Tumor Under Mixed Neuroendocrine Neoplasm (MiNEN) Protocols: A Case Report of Successful Outlier Management"],"prefix":"10.7759","author":[{"given":"Taimur","family":"Aslam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash Sankar Uday","family":"Vankayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabeen","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashna","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Niazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy","family":"Skaradinskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i11.1123","article-title":"Rectal neuroendocrine tumors: current advances in management, treatment, and surveillance","volume":"28","author":"Gallo C","year":"2022","unstructured":"Gallo C, Rossi RE, Cavalcoli F, Barbaro F, Bo\u0161koski I, Invernizzi P, Massironi S. Rectal neuroendocrine tumors: current advances in management, treatment, and surveillance. World J Gastroenterol. 2022, 28:1123-38. 10.3748\/wjg.v28.i11.1123","journal-title":"World J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13309","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours","volume":"35","author":"Rinke A","year":"2023","unstructured":"Rinke A, Ambrosini V, Dromain C, et al.. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J Neuroendocrinol. 2023, 35:e13309. 10.1111\/jne.13309","journal-title":"J Neuroendocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad325","article-title":"Combined lanreotide autogel and temozolomide treatment of progressive pancreatic and intestinal neuroendocrine tumors: the phase II SONNET Study","volume":"29","author":"Pavel M","year":"2024","unstructured":"Pavel M, Lahner H, H\u00f6rsch D, et al.. Combined lanreotide autogel and temozolomide treatment of progressive pancreatic and intestinal neuroendocrine tumors: the phase II SONNET Study. Oncologist. 2024, 29:e643-54. 10.1093\/oncolo\/oyad325","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2022.12.011","article-title":"Lung adenocarcinoma with neuroendocrine differentiation: molecular markers testing and treatment outcomes","volume":"122","author":"Chang HC","year":"2023","unstructured":"Chang HC, Chen KY, Chang YL, Shih JY, Yu CJ. Lung adenocarcinoma with neuroendocrine differentiation: molecular markers testing and treatment outcomes. J Formos Med Assoc. 2023, 122:731-7. 10.1016\/j.jfma.2022.12.011","journal-title":"J Formos Med Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000161981.58631.ab","article-title":"Neuroendocrine hepatic metastases: does aggressive management improve survival?","volume":"241","author":"Touzios JG","year":"2005","unstructured":"Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg. 2005, 241:776-83. 10.1097\/01.sla.0000161981.58631.ab","journal-title":"Ann Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld M","year":"2015","unstructured":"Heetfeld M, Chougnet CN, Olsen IH, et al.. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015, 22:657-64. 10.1530\/ERC-15-0119","journal-title":"Endocr Relat Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000503721","article-title":"Neuroendocrine neoplasms of the small bowel and pancreas","volume":"110","author":"Clift AK","year":"2020","unstructured":"Clift AK, Kidd M, Bodei L, et al.. Neuroendocrine neoplasms of the small bowel and pancreas. Neuroendocrinology. 2020, 110:444-76. 10.1159\/000503721","journal-title":"Neuroendocrinology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel CG","year":"1991","unstructured":"Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991, 68:227-32. 10.1002\/1097-0142(19910715)68:2&lt;227::aid-cncr2820680202&gt;3.0.co;2-i","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-003-0038-1","article-title":"Neuroendocrine carcinomas of the colon and rectum","volume":"47","author":"Bernick PE","year":"2004","unstructured":"Bernick PE, Klimstra DS, Shia J, et al.. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum. 2004, 47:163-9. 10.1007\/s10350-003-0038-1","journal-title":"Dis Colon Rectum"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7150\/jca.4502","article-title":"Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis","volume":"3","author":"Tsikitis VL","year":"2012","unstructured":"Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer. 2012, 3:292-302. 10.7150\/jca.4502","journal-title":"J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0557","article-title":"Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis","volume":"25","author":"Milione M","year":"2018","unstructured":"Milione M, Maisonneuve P, Pellegrinelli A, et al.. Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. Endocr Relat Cancer. 2018, 25:583-93. 10.1530\/ERC-17-0557","journal-title":"Endocr Relat Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0410","article-title":"Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity","volume":"22","author":"Sahnane N","year":"2015","unstructured":"Sahnane N, Furlan D, Monti M, et al.. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer. 2015, 22:35-45. 10.1530\/ERC-14-0410","journal-title":"Endocr Relat Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-023-09755-3","article-title":"Diagnostic, prognostic, and predictive role of Ki67 proliferative index in neuroendocrine and endocrine neoplasms: past, present, and future","volume":"34","author":"La Rosa S","year":"2023","unstructured":"La Rosa S. Diagnostic, prognostic, and predictive role of Ki67 proliferative index in neuroendocrine and endocrine neoplasms: past, present, and future. Endocr Pathol. 2023, 34:79-97. 10.1007\/s12022-023-09755-3","journal-title":"Endocr Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3395","article-title":"Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial","volume":"8","author":"Morizane C","year":"2022","unstructured":"Morizane C, Machida N, Honma Y, et al.. Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol. 2022, 8:1447-55. 10.1001\/jamaoncol.2022.3395","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/diseases9010021","article-title":"Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer","volume":"9","author":"Lakemeyer L","year":"2021","unstructured":"Lakemeyer L, Sander S, Wittau M, Henne-Bruns D, Kornmann M, Lemke J. Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer. Diseases. 2021, 9:14-6. 10.3390\/diseases9010021","journal-title":"Diseases"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes A","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al.. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023, 34:10-32. 10.1016\/j.annonc.2022.10.003","journal-title":"Ann Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger R","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, et al.. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023, 388:44-54. 10.1056\/NEJMoa2212419","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/342054-treating-a-non-mixed-neuroendocrine-colorectal-tumor-under-mixed-neuroendocrine-neoplasm-minen-protocols-a-case-report-of-successful-outlier-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:19:59Z","timestamp":1740111599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/342054-treating-a-non-mixed-neuroendocrine-colorectal-tumor-under-mixed-neuroendocrine-neoplasm-minen-protocols-a-case-report-of-successful-outlier-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.79389","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}